Home > Gastroenterology > Icotinib plus radiotherapy ups survival in elderly with esophageal cancer

Icotinib plus radiotherapy ups survival in elderly with esophageal cancer

Journal
JAMA Network Open
Reuters Health - 15/10/2020 - Icotinib with concurrent radiotherapy (RT) boosts survival and may have other benefits compared to RT alone in elderly patients with unresectable esophageal squamous cell carcinoma, according to Chinese researchers. Dr. Shixiu Wu told Reuters Health by email, "I think our trial is the first involving the combination of targeted therapy and RT in old people with esophageal cancer and we demonstrated that it improved the overall survival with less toxicity." In a paper in JAMA Network Open, Dr. Wu of the Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, and colleagues say their essential hypothesis was that the combination "would promote local and regional effects as well as diminish distant metastases." They note that in preclinical studies, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor icotinib has markedly inhibited proliferation of human epidermoid squamous carcinoma cell li...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on